INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 119 filers reported holding INFINITY PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is 0.63 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $2,000 | +100.0% | 1,000 | 0.0% | 0.00% | – |
| Q4 2018 | $1,000 | 0.0% | 1,000 | 0.0% | 0.00% | – |
| Q3 2018 | $1,000 | -50.0% | 1,000 | 0.0% | 0.00% | -100.0% |
| Q2 2018 | $2,000 | 0.0% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $2,000 | 0.0% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $2,000 | +100.0% | 1,000 | 0.0% | 0.00% | – |
| Q3 2017 | $1,000 | -50.0% | 1,000 | 0.0% | 0.00% | -100.0% |
| Q2 2017 | $2,000 | -33.3% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $3,000 | +200.0% | 1,000 | 0.0% | 0.00% | – |
| Q4 2016 | $1,000 | -50.0% | 1,000 | 0.0% | 0.00% | -100.0% |
| Q3 2016 | $2,000 | 0.0% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $2,000 | -60.0% | 1,000 | 0.0% | 0.00% | -50.0% |
| Q1 2016 | $5,000 | -28.6% | 1,000 | 0.0% | 0.00% | -33.3% |
| Q4 2015 | $7,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,354,963 | $38,132,000 | 1.80% |
| Orbimed Advisors | 4,520,800 | $73,201,000 | 1.55% |
| QVT Financial LP | 1,326,610 | $21,480,000 | 1.44% |
| BB BIOTECH AG | 1,089,828 | $17,646,000 | 1.27% |
| Meditor Group Ltd | 250,000 | $4,048,000 | 0.55% |
| Perimeter Capital Partners, LLC | 159,915 | $2,589,000 | 0.50% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 156,808 | $2,539,000 | 0.43% |
| Broadfin Capital, LLC | 117,172 | $1,897,000 | 0.37% |
| OXFORD ASSET MANAGEMENT LLP | 811,331 | $13,184,000 | 0.36% |
| Baker Brothers Advisors | 1,016,433 | $16,458,000 | 0.33% |